Cornell researchers have developed a groundbreaking biosensor that offers an unprecedented level of insight into the inner workings of cells. This new technology, called ProKAS (Proteomic Kinase Activity Sensors), allows scientists to study the intricate dance of kinases, the enzymes that orchestrate cellular processes, with remarkable precision.
Kinases are the cellular conductors that manage everything from metabolism to growth and stress responses. With over 500 kinases in human cells, understanding their coordinated actions is a complex challenge. Until now, researchers have struggled to observe these enzymes' activities within living cells, hindering progress in drug development and cellular biology.
The ProKAS technique, developed by Professor Marcus Smolka's team, employs a clever strategy. It uses amino acid chains, or peptides, engineered to mimic the natural targets of kinases. Each peptide carries a unique 'barcode' that reveals its location within the cell. When a kinase acts on the peptide, mass spectrometry detects both the action and the barcode, providing a detailed map of kinase activity, location, and timing.
In a recent study, Smolka's team utilized ProKAS to monitor kinase activity during cells' response to anti-cancer drugs that cause DNA damage. The use of barcodes, previously applied in genomics, was a key innovation. This approach allowed the researchers to track multiple kinases simultaneously, revealing the timing and location of their actions with unprecedented detail.
The researchers observed how key DNA damage response kinases, such as ATR, ATM, and CHK1, reacted over time, uncovering differences in activity across cell regions that were previously undetectable. ProKAS' efficiency is impressive, handling many samples quickly, making it scalable for larger studies.
Will Comstock, a former researcher in Smolka's lab, highlights the scalability of ProKAS, noting that they can analyze 36 samples in a 30-minute mass spectrometry run, and aim to process hundreds or even thousands in the future.
ProKAS' versatility extends beyond its current applications. Smolka suggests that it could be adapted to study other human kinases, aiding pharmaceutical research. This technology could accelerate the identification of new drugs that target kinase activity in disease processes, offering a valuable tool for drug development.
Looking ahead, the team plans to integrate ProKAS with computational design tools and expanded peptide libraries to further enhance our understanding of kinase-driven cell behavior. This cutting-edge research promises to unlock new insights into cellular processes and drug development, marking a significant advancement in the field of biology.
